1: Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis: Am J Respir Crit Care Med. 2011, 15;183(4):431-40.
2: Kaner RJ, Bajwa EK, El-Amine M, Gorina E, Gupta R, Lazarus HM, Luckhardt TR, Mouded M, Posada K, Richeldi L, Stauffer J, Tutuncu A, Martinez FJ: Design of idiopathic pulmonary fibrosis clinical trials in the era of approved therapies. Am J Respir Crit Care Med. 2019, 15;200(2):133-139.
3: Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE Jr, Ryu JH, Collard HR: Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012, 67(5):407-11.
4: du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr: 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2014, 43(5):1421-9.
5: du Bois RM, Nathan SD, Richeldi L, Schwarz MI, Noble PW: Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med. 2012, 15;186(8):712-5.
6: Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, Raghu G, King TE Jr, Bradford WZ, Schwartz DA, Richard Webb W, Idiopathic Pulmonary Fibrosis Study Group: High-resolution computed tomography in idiopathic pulmonary fibrosis, diagnosis and prognosis. Am J Respir Crit Care Med. 2005, 15;172(4):488-93.
7: King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW, ASCEND Study Group: A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014, 29;370(22):2083-92.
8: Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR, INPULSIS Trial Investigators: Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014, 29;370(22):2071-82.
9: Yoo DK, Zompatori M, Barrile A, Rossi G, D'Amato D, Sergiacomi G, Rogliani P, Mura M: Associated pulmonary hypertension is an independent contributor to exercise intolerance in chronic fibrosing interstitial pneumonias. Respiration. 2018;96(6):543-551.
10: Salisbury ML, Lynch DA, van Beek EJ, Kazerooni EA, Guo J, Xia M, Murray S, Anstrom KJ, Yow E, Martinez FJ, Hoffman EA, Flaherty KR, IPFnet Investigators: Idiopathic pulmonary fibrosis: the association between the adaptive multiple features method and fibrosis outcomes. Am J Respir Crit Care Med. 2017, 1;195(7):921-929.
11: Humphries SM, Swigris JJ, Brown KK, Strand M, Gong Q, Sundy JS, Raghu G, Schwarz MI, Flaherty KR, Sood R, O'Riordan TG, Lynch DA: Quantitative high-resolution computed tomography fibrosis score, performance characteristics in idiopathic pulmonary fibrosis. Eur Respir J. 2018,17;52(3).
12: Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Nair A, Karwoski R, Raghunath SM, Walsh SL, Wells AU, Hansell DM: Automated quantitative computed tomography versus visual computed tomography scoring in idiopathic pulmonary fibrosis, validation against pulmonary function. J Thorac Imaging. 2016, 31(5):304-11.
13: Park HJ, Lee SM, Song JW, Lee SM, Oh SY, Kim N, Seo JB: Texture-based automated quantitative assessment of regional patterns on initial CT in patients with idiopathic pulmonary fibrosis, relationship to decline in forced vital capacity. AJR Am J Roentgenol. 2016, 207(5):976-983. Epub 2016 Aug 17. PubMed PMID: 27533069.
14: Watadani T, Sakai F, Johkoh T, Noma S, Akira M, Fujimoto K, Bankier AA, Lee KS, Müller NL, Song JW, Park JS, Lynch DA, Hansell DM, Remy-Jardin M, Franquet T, Sugiyama Y: Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology. 2013, 266(3):936-44.
15: Walsh SL, Calandriello L, Sverzellati N, Wells AU, Hansell DM, UIP Observer Consort: Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT. Thorax. 2016, 71(1):45-51.
16: Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP 3rd, Martinez FJ: Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003, 1;168(5):543-8.
17: Sverzellati N, Silva M, Seletti V, Galeone C, Palmucci S, Piciucchi S, Vancheri C, Poletti V, Tomassetti S, Karwoski R, Bartholmai BJ: Stratification of long-term outcome in stable idiopathic pulmonary fibrosis by combining longitudinal computed tomography and forced vital capacity. Eur Radiol. 2020, Jan 31. doi: 10.1007/s00330-019-06619-5.
18: King TE Jr, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, Schwartz DA: Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest. 2005, 127(1):171-7.
19: Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU: Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity, analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax. 2016, 71(5):429-35.
20: Kreuter M, Koegler H, Trampisch M, Geier S, Richeldi L: Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials. Respir Res. 2019, 20(1):71.
21: Humphries SM, Yagihashi K, Huckleberry J, Rho BH, Schroeder JD, Strand M, Schwarz MI, Flaherty KR, Kazerooni EA, van Beek EJR, Lynch DA: Idiopathic pulmonary fibrosis: data-driven textural analysis of extent of fibrosis at baseline and 15-month follow-up. Radiology. 2017, 285(1):270-278.
22: Clukers J, Lanclus M, Mignot B, Van Holsbeke C, Roseman J, Porter S, Gorina E, Kouchakji E, Lipson KE, De Backer W, De Backer J: Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity. Respir Res. 2018, 6;19(1):213.
23: Hwang JH, Misumi S, Curran-Everett D, Brown KK, Sahin H, Lynch DA: Longitudinal follow-up of fibrosing interstitial pneumonia: relationship between physiologic testing, computed tomography changes, and survival rate. J Thorac Imaging. 2011, 26(3):209-17.
24: Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Egashira R, Brun AL, Nair A, Walsh SLF, Karwoski R, Wells AU: Serial automated quantitative CT analysis in idiopathic pulmonary fibrosis: functional correlations and comparison with changes in visual CT scores. Eur Radiol. 2018, 28(3):1318-1327.
25: Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A, Mezzasalma F, Rottoli P, Saltini C, Rogliani P: Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J. 2012, 40(1):101-9.
26: Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society: Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018, 1;198(5):e44-e68.
27: Flaherty KR, King TE Jr, Raghu G, Lynch JP 3rd, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, Murray S, Lama VN, Gay SE, Martinez FJ: Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004, 15;170(8):904-10.
28: Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force: Standardisation of spirometry. Eur Respir J. 2005, 26(2):319-38.
29: Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G: Standardisation of the measurement of lung volumes. Eur Respir J. 2005, 26(3):511-22.
30: Graham BL, Brusasco V, Burgos F, Cooper BG, Jensen R, Kendrick A, MacIntyre NR, Thompson BR, Wanger J: 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J. 2017, 3;49(1).
31: Brennan P, Silman A: Statistical methods for assessing observer variability in clinical measures. BMJ. 1992, 6;304(6840):1491-4.
32: Slinker BY, Glantz SA: Multiple regression for physiological data analysis: the problem of multicollinearity. Am J Phys. 1985, 249:R1-R12.
33: Ley B. Counterpoint: hould molecular and genetic biomarkers be used in the initial evaluation of patients with fibrotic ILD? No. Chest. 2019, 156(2):205-208.
34: Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Nair A, Karwoski R, Raghunath SM, Walsh SL, Wells AU, Hansell DM: Automated quantitative computed tomography versus visual computed tomography scoring in idiopathic pulmonary fibrosis: validation against pulmonary function. J Thorac Imaging. 2016, 31(5):304-11.
35: King CS, Nathan SD: Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med. 2017, 5(1):72-84.
36: Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J: Interpretative strategies for lung function tests. Eur Respir J. 2005, 26(5):948-68.
37: Lee SM, Seo JB, Oh SY, Kim TH, Song JW, Lee SM, Kim N: Prediction of survival by texture-based automated quantitative assessment of regional disease patterns on CT in idiopathic pulmonary fibrosis. Eur Radiol. 2018, 28(3):1293-1300.